[{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"TG01","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Targovax \/ IOVaxis Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ IOVaxis Therapeutics"},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"TG01","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Targovax \/ IOVaxis","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ IOVaxis"},{"orgOrder":0,"company":"Targovax","sponsor":"Innovation Norway","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Gemcitabine","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Targovax \/ Innovation Norway","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Innovation Norway"},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"QS-21 Stimulon","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Targovax \/ Agenus","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ Agenus"}]

Find Clinical Drug Pipeline Developments & Deals for Apricoxib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the collaboration with Targovax, Agenus will supply QS-21 STIMULON and scientific support for up to three initial TG01 clinical trials in different cancer indications.

                          Brand Name : TG01

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 07, 2022

                          Lead Product(s) : Apricoxib,Stimulon

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Agenus

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : With the support from Innovation Norway, Targovax has move the TG program forward faster and more broadly, and thus bring benefit to a patient group with poor prognosis and few available treatment options.

                          Brand Name : TG01

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 12, 2022

                          Lead Product(s) : Apricoxib,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Innovation Norway

                          Deal Size : $0.9 million

                          Deal Type : Funding

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore...

                          Brand Name : TG01

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 06, 2021

                          Lead Product(s) : Apricoxib

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : IOVaxis Therapeutics

                          Deal Size : $3.0 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the agreement, IOVaxis and Targovax will jointly define a development plan in the territory, and IOVaxis will be responsible for all local regulatory filings and will sponsor clinical trials.

                          Brand Name : TG01

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 08, 2020

                          Lead Product(s) : Apricoxib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : IOVaxis Therapeutics

                          Deal Size : $100.0 million

                          Deal Type : Licensing Agreement

                          blank